-
Conjustar announced the completion of ￥100 million Pre-A+ round of financing
Conjustar announced the completion of ￥100 million Pre-A+ round of financing. This round of financing was led by Fosun health Capital New Drug Innovation Fund of Fosun Pharmaceutical, and co-invested by Hengqin Venture Capital and Shenzhen Qianhai Liyuan.
넶1 2025-03-25 -
Key Milestone | Completion of the first patient enrolled in the phase I study of the PDC SC-102
December 20, 2024, Conjustar announced that the first patient has been enrolled in the Phase I clinical trial of SC-102, the first novel PDC targeting EphA2 in China. The trial is being conducted at the Fudan University Shanghai Cancer Center.
넶252 2024-12-26 -
Investigational new drug (IND) application of SC-102 was approved by CDE of NMPA
On August 8, 2024, Conjustar Biologics announced that the investigational new drug (IND) application for the company's second peptide-drug conjugate (PDC), SC-102 for Injection, for the treatment of advanced malignant solid tumors expressing EphA2, was approved by the Center for Drug Evaluation (CDE) of the Chinese National Medical Products Administration.
넶292 2024-09-02 -
SC-101 has received Investigational New Drug (IND) approval from the U.S. Food and Drug
On May 31, 2024, Conjustar Biologics announced that its Nectin-4 targeting PDC drug SC-101 has received Investigational New Drug (IND) approval from the U.S. Food and Drug.
넶198 2024-05-31
